Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2008 2
2009 1
2010 8
2011 7
2012 15
2013 17
2014 10
2015 28
2016 48
2017 41
2018 26
2019 22
2020 17
2021 17
2022 12
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Panobinostat for the Treatment of Multiple Myeloma.
Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, Gavriatopoulou M, Terpos E, Dimopoulos MA. Eleutherakis-Papaiakovou E, et al. J Oncol. 2020 Jan 13;2020:7131802. doi: 10.1155/2020/7131802. eCollection 2020. J Oncol. 2020. PMID: 32411240 Free PMC article. Review.
In order to further explore its clinical potential, it is evaluated in different combinations in relapsed/refractory and newly diagnosed multiple myeloma. This review focuses on available data about panobinostat's pharmacology and its role in clinical practic …
In order to further explore its clinical potential, it is evaluated in different combinations in relapsed/refractory and newly diagnosed …
Panobinostat for the management of multiple myeloma.
Sivaraj D, Green MM, Gasparetto C. Sivaraj D, et al. Future Oncol. 2017 Mar;13(6):477-488. doi: 10.2217/fon-2016-0329. Epub 2016 Oct 25. Future Oncol. 2017. PMID: 27776419 Review.
Multiple myeloma (MM) is the second most common blood cancer following non-Hodgkin's lymphoma. ...It was US FDA approved in February 2015 for the management of relapsed/refractory MM in combination with bortezomib and dexamethasone. Several trials are ongoing, explo …
Multiple myeloma (MM) is the second most common blood cancer following non-Hodgkin's lymphoma. ...It was US FDA approved in Fe …
panobinostat (FARYDAK). Multiple myeloma: too toxic!
[No authors listed] [No authors listed] Prescrire Int. 2016 Nov;25(176):257-259. Prescrire Int. 2016. PMID: 30715819 Review.
Patients with relapsed or refractory multiple myeloma who have received several lines of therapy have no satisfactory treatment options. ...A randomised, double-blind, placebo-controlled trial evaluated panobinostat in 768 patients with relapsed or refractory …
Patients with relapsed or refractory multiple myeloma who have received several lines of therapy have no satisfactory treatmen …
Panobinostat for the Treatment of Multiple Myeloma.
Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Laubach JP, et al. Clin Cancer Res. 2015 Nov 1;21(21):4767-73. doi: 10.1158/1078-0432.CCR-15-0530. Epub 2015 Sep 11. Clin Cancer Res. 2015. PMID: 26362997 Review.
Panobinostat was approved based on results from the phase III PANORAMA 1 trial in patients with relapsed or relapsed and refractory multiple myeloma, which showed that panobinostat plus bortezomib and dexamethasone significantly extended progression-fr …
Panobinostat was approved based on results from the phase III PANORAMA 1 trial in patients with relapsed or relapsed and refractory …
Panobinostat for the treatment of multiple myeloma: the evidence to date.
Bailey H, Stenehjem DD, Sharma S. Bailey H, et al. J Blood Med. 2015 Oct 8;6:269-76. doi: 10.2147/JBM.S69140. eCollection 2015. J Blood Med. 2015. PMID: 26504410 Free PMC article. Review.
Multiple myeloma is a malignancy involving plasma cell proliferation within the bone marrow. ...Panobinostat for multiple myeloma is used in combination with other potent therapeutic agents, such as proteasome inhibitors and steroids. ...
Multiple myeloma is a malignancy involving plasma cell proliferation within the bone marrow. ...Panobinostat for mul …
Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.
Berdeja JG, Laubach JP, Richter J, Stricker S, Spencer A, Richardson PG, Chari A. Berdeja JG, et al. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):752-765. doi: 10.1016/j.clml.2021.06.020. Epub 2021 Jun 26. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34340951 Review.
Relapsed and refractory multiple myeloma (RRMM) presents a therapeutic challenge due to the development of drug resistance. ...Panobinostat is a promising HDACi for the treatment of multiple myeloma. ...
Relapsed and refractory multiple myeloma (RRMM) presents a therapeutic challenge due to the development of drug resistance. .. …
Outcomes with panobinostat in heavily pretreated multiple myeloma patients.
Pan D, Mouhieddine TH, Upadhyay R, Casasanta N, Lee A, Zubizarreta N, Moshier E, Richter J. Pan D, et al. Semin Oncol. 2023 Feb-Apr;50(1-2):40-48. doi: 10.1053/j.seminoncol.2023.03.006. Epub 2023 Mar 24. Semin Oncol. 2023. PMID: 37005144
Panobinostat is an oral pan histone-deacetylase inhibitor used in the treatment of relapsed and refractory multiple myeloma. ...The most common toxicities grade 3 were hematologic, primarily neutropenia (34.3%), thrombocytopenia (27.6%), and anemia (19.1%). …
Panobinostat is an oral pan histone-deacetylase inhibitor used in the treatment of relapsed and refractory multiple myeloma …
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Dimopoulos MA, Richardson P, Lonial S. Dimopoulos MA, et al. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):460-473. doi: 10.1016/j.clml.2022.01.011. Epub 2022 Jan 19. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35148975 Free article. Review.
Despite the increasing number of treatment options available for multiple myeloma, relapse is still inevitable and there remains a critical unmet need for treatments for patients with late-stage, highly refractory disease. In this review, we discuss currently approv …
Despite the increasing number of treatment options available for multiple myeloma, relapse is still inevitable and there remai …
Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.
Greig SL. Greig SL. Target Oncol. 2016 Feb;11(1):107-14. doi: 10.1007/s11523-015-0413-6. Target Oncol. 2016. PMID: 26826025 Review.
Oral panobinostat (Farydak), a potent nonselective histone deacetylase inhibitor, is approved in several countries for use in combination with bortezomib and dexamethasone in patients with multiple myeloma (MM) [USA] or relapsed and/or refractory MM (EU) who …
Oral panobinostat (Farydak), a potent nonselective histone deacetylase inhibitor, is approved in several countries for use in combina …
Panobinostat for the treatment of multiple myeloma.
Neri P, Bahlis NJ, Lonial S. Neri P, et al. Expert Opin Investig Drugs. 2012 May;21(5):733-47. doi: 10.1517/13543784.2012.668883. Epub 2012 Mar 12. Expert Opin Investig Drugs. 2012. PMID: 22404247 Review.
INTRODUCTION: Multiple myeloma (MM) is a B-cell malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. ...AREA COVERED: In this review the authors discuss the role of HDACs in the regulation of gene expression and the biological mec …
INTRODUCTION: Multiple myeloma (MM) is a B-cell malignancy characterized by proliferation of monoclonal plasma cells in the bo …
250 results